Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · Real-Time Price · USD
1.550
+0.080 (5.44%)
Jun 18, 2025, 4:00 PM - Market closed
Anebulo Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts that cover Anebulo Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $5.5, which forecasts a 254.84% increase in the stock price over the next year. The lowest target is $3 and the highest is $8.
Price Target: $5.5 (+254.84%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2025.
Analyst Ratings
The average analyst rating for Anebulo Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $6 → $3 | Strong Buy | Maintains | $6 → $3 | +93.55% | May 15, 2025 |
| Benchmark | Benchmark | Buy Reiterates $8 | Buy | Reiterates | $8 | +416.13% | Nov 19, 2024 |
| Benchmark | Benchmark | Buy Reiterates $8 | Buy | Reiterates | $8 | +416.13% | Oct 1, 2024 |
| Benchmark | Benchmark | Buy Reiterates $8 | Buy | Reiterates | $8 | +416.13% | Oct 3, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +287.10% | Sep 25, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.30
from -0.32
EPS Next Year
-0.49
from -0.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.27 | -0.50 | -0.48 |
| Avg | -0.30 | -0.49 | -0.47 |
| Low | -0.31 | -0.47 | -0.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.